NO20091628L - Kombinasjonsmedikament - Google Patents

Kombinasjonsmedikament

Info

Publication number: NO20091628L
Authority: NO; Norway
Prior art keywords: combination drug; combination; disclosed; agent; hormonal
Prior art date: 2006-10-06

Application number

NO20091628A

Other languages

English (en)

Norwegian (no)

Inventor

Yoshikazu Ohta

Toshiya Tamura

Shinji Takagi

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-06

Filing date

2009-04-23

Publication date

2009-06-26

2009-04-23 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2009-06-26 Publication of NO20091628L publication Critical patent/NO20091628L/no

Links

229940000425 combination drug Drugs 0.000 title 1
229940125497 HER2 kinase inhibitor Drugs 0.000 abstract 2
239000002246 antineoplastic agent Substances 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
230000003054 hormonal effect Effects 0.000 abstract 2
239000008177 pharmaceutical agent Substances 0.000 abstract 2
KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical group N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 abstract 1
OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical group C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO20091628A 2006-10-06 2009-04-23 Kombinasjonsmedikament NO20091628L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2006275841		2006-10-06
JP2007057902		2007-03-07
PCT/JP2007/070026 WO2008044782A2 (en)	2006-10-06	2007-10-05	Combination drug

Publications (1)

Publication Number	Publication Date
NO20091628L true NO20091628L (no)	2009-06-26

Family

ID=39283276

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091628A NO20091628L (no)	2006-10-06	2009-04-23	Kombinasjonsmedikament

Country Status (23)

Country	Link
US (1)	US20100008912A1 (pt)
EP (2)	EP2063895A2 (pt)
JP (1)	JP2010505745A (pt)
KR (1)	KR20090094804A (pt)
CN (1)	CN101553222A (pt)
AR (1)	AR063152A1 (pt)
AU (1)	AU2007307489A1 (pt)
BR (1)	BRPI0717477A2 (pt)
CA (1)	CA2665692A1 (pt)
CL (1)	CL2007002878A1 (pt)
CO (1)	CO6180429A2 (pt)
CR (1)	CR10759A (pt)
EA (1)	EA200970353A1 (pt)
EC (1)	ECSP099311A (pt)
GE (1)	GEP20115218B (pt)
IL (1)	IL197883A0 (pt)
MA (1)	MA30815B1 (pt)
MX (1)	MX2009003660A (pt)
NO (1)	NO20091628L (pt)
PE (1)	PE20080977A1 (pt)
TN (1)	TN2009000119A1 (pt)
TW (1)	TW200823218A (pt)
WO (1)	WO2008044782A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MEP8409A (en) *	2004-06-02	2011-12-20		Fused heterocyclic compound
US20100183604A1 (en)	2007-06-19	2010-07-22	Takeda Pharmaceutical Company Limited	Preventive/remedy for cancer
US8946239B2 (en)	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2011040212A1 (en)	2009-10-01	2011-04-07	Takeda Pharmaceutical Company Limited	Therapeutic agent for brain tumor
KR101592258B1 (ko) *	2014-06-20	2016-02-05	보령제약 주식회사	제제 및 이의 제조방법
US10317014B2 (en) *	2016-08-09	2019-06-11	Baker Hughes, A Ge Company, Llc	Flow variation system
EP4121130A4 (en) *	2020-03-17	2024-03-27	MicroVention, Inc.	LIQUID EMBOLIZATION AGENTS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU33730B (en) *	1967-04-18	1978-02-28	Farmaceutici Italia	Process for preparing a novel antibiotic substance and salts thereof
JPS6019790A (ja) *	1983-07-14	1985-01-31	Yakult Honsha Co Ltd	新規なカンプトテシン誘導体
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1989006692A1 (en) *	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
US6136846A (en) *	1999-10-25	2000-10-24	Supergen, Inc.	Formulation for paclitaxel
EP1545533A1 (en) *	2002-09-04	2005-06-29	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4366683B2 (ja)	2003-07-28	2009-11-18	武原力	熱サイホン
MEP8409A (en) *	2004-06-02	2011-12-20		Fused heterocyclic compound
MXPA06013952A (es)	2004-06-04	2007-02-08	Smithkline Beecham Cork Ltd	Metodo para el tratamiento de cancer.
JP5334414B2 (ja) *	2004-09-06	2013-11-06	バイエルインテレクチュアルプロパティーゲゼルシャフトミットベシュレンクテルハフツング	新規のピラゾロピリミジン
JP2006275841A (ja)	2005-03-30	2006-10-12	Taiheiyo Cement Corp	セメント中のジエチレングリコール量の定量方法
JP2007057902A (ja)	2005-08-25	2007-03-08	Seiko Epson Corp	画像形成装置

2007
- 2007-10-05 AU AU2007307489A patent/AU2007307489A1/en not_active Abandoned
- 2007-10-05 CA CA002665692A patent/CA2665692A1/en not_active Abandoned
- 2007-10-05 EP EP07829761A patent/EP2063895A2/en not_active Withdrawn
- 2007-10-05 PE PE2007001354A patent/PE20080977A1/es not_active Application Discontinuation
- 2007-10-05 EA EA200970353A patent/EA200970353A1/ru unknown
- 2007-10-05 US US12/444,309 patent/US20100008912A1/en not_active Abandoned
- 2007-10-05 MX MX2009003660A patent/MX2009003660A/es not_active Application Discontinuation
- 2007-10-05 BR BRPI0717477-2A patent/BRPI0717477A2/pt not_active IP Right Cessation
- 2007-10-05 CL CL200702878A patent/CL2007002878A1/es unknown
- 2007-10-05 JP JP2009514289A patent/JP2010505745A/ja not_active Abandoned
- 2007-10-05 EP EP11156096A patent/EP2359825A2/en not_active Withdrawn
- 2007-10-05 WO PCT/JP2007/070026 patent/WO2008044782A2/en not_active Ceased
- 2007-10-05 CN CNA2007800453762A patent/CN101553222A/zh active Pending
- 2007-10-05 KR KR1020097009034A patent/KR20090094804A/ko not_active Withdrawn
- 2007-10-05 TW TW096137401A patent/TW200823218A/zh unknown
- 2007-10-05 GE GEAP200711244A patent/GEP20115218B/en unknown
- 2007-10-09 AR ARP070104424A patent/AR063152A1/es not_active Application Discontinuation
2009
- 2009-04-03 TN TNP2009000119A patent/TN2009000119A1/fr unknown
- 2009-04-05 IL IL197883A patent/IL197883A0/en unknown
- 2009-04-23 NO NO20091628A patent/NO20091628L/no not_active Application Discontinuation
- 2009-04-27 MA MA31822A patent/MA30815B1/fr unknown
- 2009-04-30 CR CR10759A patent/CR10759A/es unknown
- 2009-05-05 EC EC2009009311A patent/ECSP099311A/es unknown
- 2009-05-06 CO CO09045382A patent/CO6180429A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20100008912A1 (en)	2010-01-14
CL2007002878A1 (es)	2008-08-01
EP2063895A2 (en)	2009-06-03
MA30815B1 (fr)	2009-10-01
MX2009003660A (es)	2009-04-22
BRPI0717477A2 (pt)	2015-06-16
KR20090094804A (ko)	2009-09-08
WO2008044782A2 (en)	2008-04-17
ECSP099311A (es)	2009-06-30
WO2008044782A3 (en)	2008-12-11
EA200970353A1 (ru)	2009-10-30
TN2009000119A1 (en)	2010-10-18
EP2359825A2 (en)	2011-08-24
AU2007307489A1 (en)	2008-04-17
IL197883A0 (en)	2009-12-24
CO6180429A2 (es)	2010-07-19
AR063152A1 (es)	2008-12-30
CN101553222A (zh)	2009-10-07
TW200823218A (en)	2008-06-01
GEP20115218B (en)	2011-05-25
JP2010505745A (ja)	2010-02-25
CR10759A (es)	2009-05-27
CA2665692A1 (en)	2008-04-17
PE20080977A1 (es)	2008-09-05

Legal Events

Date	Code	Title	Description
2012-06-04	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
IL274602A (en)	2020-06-30	Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
CL2007003523A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
EA200802184A1 (ru)	2009-06-30	Фармацевтические композиции с ингибиторами dpp iv
MY143407A (en)	2011-05-13	Indazole derivatives as inhibitors of hormone sensitive lipase
DK3248600T3 (da)	2020-07-06	Kombinationer og måder til administration af terapeutiske stoffer og kombinationsterapi
CL2007001724A1 (es)	2008-05-09	Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
AR047928A1 (es)	2006-03-01	Derivados de tetrahidropiridoindol
CY1107906T1 (el)	2013-09-04	Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
SV2006002100A (es)	2006-02-15	Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos ref. p-sv-78.159/msu
DE602005003343D1 (de)	2007-12-27	Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
GT200600260A (es)	2008-01-03	Derivados de benzamida y usos relacionados con los mismos
ATE490967T1 (de)	2010-12-15	18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
BRPI0717369A2 (pt)	2014-10-07	Composto, medicamento, composição farmacêutica que o contém e uso do composto.
TN2009000119A1 (en)	2010-10-18	Combination drug
IL183481A0 (en)	2007-09-20	Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives
MX2009001433A (es)	2009-04-09	Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
TNSN08385A1 (en)	2009-12-29	Delayed-release glucocorticoid treatment of rheumatoid disease
BRPI0513938B8 (pt)	2021-05-25	composição farmacêutica contendo drospirenona e etinilestradiol
DK1869185T3 (da)	2010-06-21	Konjugat med P21-protein til kræftbehandling
CL2011000252A1 (es)	2011-11-18	Uso de estriol para preparar un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres.
MXPA05009849A (es)	2005-12-06	Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
ATE410154T1 (de)	2008-10-15	Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
BRPI0512316A (pt)	2008-02-26	métodos para prevenir ou atenuar uma ou mais complicações da hemorragia intracerebral e para prevenir ou atenuar uma ou mais complicações da ich em uma maioria de pacientes com ich, e, uso de um primeiro agente de coagulação
UY28762A1 (es)	2005-08-31	Nuevos compuestos
WO2010042600A3 (en)	2010-07-22	Photo-activatable therapeutic agents and methods of using